Safety of ephedra and related anorexic medications

Bibliography

• Eisenberg DM, Davis, RB, Ettner, SL, et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA 1998;280:1569
   PubMed Web of Science ®Google Scholar
• Price RA. Systematics of the Gnetales: a review of morphological and molecular evidence. Int J Plant Sci 1996;157(6)(Suppl): Biology and Evolution of Gnetales S40-9
   Google Scholar
• Caveney S, Charlet DA, Freitag H, et al. New observations on the secondary chemistry of world ephedra. Am J Bot 2001;88(7):1199-208
   PubMed Web of Science ®Google Scholar
• Meyer SE. Ephedra. Provo, UT: USDA Forest Service, Rocky Mountain Research Station; 1995
   Google Scholar
• Hickman JC. Ed. The Jepson Manual: higher plants of California. Berkeley and Los Angeles, CA: University of California Pre; 1993
   Google Scholar
• Betz JM, Gay ML, Mossoba MM, et al. Chiral gas chromatographic determination of ephedrine-type alkaloids in dietary supplements containing Ma Huang. J AOAC Int 1997;80:303
   PubMed Web of Science ®Google Scholar
• Redman CM, Druce, HM. Nonprescription bronchodilator use in asthma. Chest 1998;11:657
   Google Scholar
• Langwinski R. Central effects of ephedrine. Pol Tyg Lek 1972;27:1205
   PubMedGoogle Scholar
• Unger DL. Blood pressure and pulse rate changes in hypertensive asthmatic patients: effects of an ephedrine compound. Ann Allergy 1968;26:637
   PubMedGoogle Scholar
• Meston CM, Heiman JR. Ephedrine-activated physiological sexual arousal in women. Arch Gen Psychiatry 1998;55:652
   PubMed Web of Science ®Google Scholar
• Rados C. FDA Consum. Ephedra ban: no shortage of reasons. 2004;38(2):6-7
   Google Scholar
• Fleming RM. The effect of ephedra and high fat dieting – a cause for concern! A case report. Angiology 2007;58:102-5
   PubMed Web of Science ®Google Scholar
• Fleming RM. The Longitudinal effects of Fenfluramine-Phentermine use. Angiology 2007;58:353-9
   PubMed Web of Science ®Google Scholar
• Pickup ME, May CS, Sendagire R, et al. The pharmacokinetics of ephedrine after oral dosage in asthmatics receiving acute and chronic treatment. Br J Clin Pharmacol 1976;3:123
   PubMed Web of Science ®Google Scholar
• Sten GC. Requirements for pharmacists dispensing ephedrine products. Am J Health Syst Pharm 1995;52:1630
   PubMed Web of Science ®Google Scholar
• Fleming RM, Harrington GM. What is the relationship between myocardial perfusion imaging and coronary artery disease risk factors and markers of inflammation? Angiology 2008;59 (In press)
   PubMedGoogle Scholar
• Bennett R, Adams B, French A, et al. High-dose chromium(III) supplementation has no effects on body mass and composition while altering plasma hormone and triglycerides concentrations. Biol Trace Elem Res 2006;113(1):53-66
   PubMed Web of Science ®Google Scholar
• Bailey MM, Sturdivant J, Jernigan PL, et al. Comparison of the potential for developmental toxicity of prenatal exposure to two dietary chromium supplements, chromium picolinate and [Cr(3)O(O(2)CCH(2)CH(3))(6)(H(2)O)(3)](+), in mice. Birth Defects Res B Dev Reprod Toxicol 2008;83(1):27-31
   PubMed Web of Science ®Google Scholar
• Rubio MA, Gargallo M, Isabel Millán A, Moreno B. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public Health Nutr 2007;10(10A):1200-5
   PubMed Web of Science ®Google Scholar
• Fleming RM. Caloric intake, not carbohydrate or fat consumption, determines weight loss. Am J Med 2003;114:78
   PubMed Web of Science ®Google Scholar
• Neuhouser ML, Rock CL, Kristal AR, et al. Olestra is associated with slight reductions in serum carotenoids but does not markedly influence serum fat-soluble vitamin concentrations. Am J Clin Nutr 2006;83:624-31
   PubMed Web of Science ®Google Scholar
• Wilfley DE, Crow SJ, Hudson JI, et al. The Sibutramine Binge Eating Disorder Research Group. Efficacy of sibutramine for the treatment of Binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 2007;[Epub ahead of print]
   PubMedGoogle Scholar
• Scheen AJ. Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007;21(4):535-53
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group. Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353(20):2121-34
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Weight issues for people with epilepsy-A review. Epilepsia 2007;48(Suppl 9):42-5
   PubMedGoogle Scholar
• Klein KM, Theisen F, Knake S, et al. Topiramate, nutrition and weight change: a prospective study. J Neurol Neurosurg Psychiatry 2007; [Epub ahead of print]
   Google Scholar
• Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007;68(9):1324-32
   PubMed Web of Science ®Google Scholar
• Liu QS, Wang QJ, Du GH, et al. Recombinant human ciliary neurotrophic factor reduces weight partly by regulating nuclear respiratory factor 1 and mitochondrial transcription factor A. Eur J Pharmacol 2007;563(1-3):77-82. Epub 2007 Feb 27
   PubMed Web of Science ®Google Scholar
• Rezkalla SH, Mesa J, Sharma P, et al. Myocardial infarction temporally related to ephedra–a possible role for the coronary microcirculation. WMJ 2002;101:64-6
   PubMedGoogle Scholar
• van der Hooft CS, Stricker BH. Ephedrine and ephedra in weight loss products and other preparations. Ned Tijdschr Geneeskd 2002;146:1335-6
   PubMedGoogle Scholar
• Ernst E. Cardiovascular adverse effects of herbal medicines: a systematic review of the recent literature. Can J Cardiol 2003;19(7):818-27
   Google Scholar
• Bernachon-Agache F, Bernachon E, Coussieu C, et al. Leptin and old person's nutrition. J Nutr Health Aging 2005;9:327-9
   PubMed Web of Science ®Google Scholar
• Berk ES, Kovera AJ, Boozier CN, et al. Adiponectin levels during low- and high-fat eucaloric diets in lean and obese women. Obes Res 2005;13:1566-71
   PubMedGoogle Scholar
• Rouher R, Cantat A. Anorectic drugs and retinal venous complications. Ann Oculaist 1962;195:667-8
   PubMedGoogle Scholar
• Takahashi T, Wagenvoort CA. Density of muscularized arteries in the lung: its role in congenital heart disease and its clinical significance. Arch Pathol Lab Med 1983;107:23-8
   PubMed Web of Science ®Google Scholar
• Gertsch M, Stucki P. Weitgenhend reversibele primar vaskulare pulmonale hypertonie bei einem patienten mit menocil-einnahme. Z Kreislaufforsch 1970;59:902
   PubMedGoogle Scholar
• Stuart KL, Bras G. Veno-occlusive disease of the liver. Q J Med 1957;26:291. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with Fenfluramine-phentermine. N Engl J Med 1997;337:581-8
   PubMedGoogle Scholar
• Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713-8
   PubMed Web of Science ®Google Scholar
• Jick H, Vasilakis C, Weinrauch LA, et al. A population based study on appetite suppressant drugs and the risk of cardiac valve regurgitation. N Engl J Med 1998;339:719-24
   PubMed Web of Science ®Google Scholar
• Weissman NJ. Appetite suppressant valvulopathy: a review of current data. CVR & R 1999;146-55
   Google Scholar
• Burger AJ, Sherman HB, Charlamb MJ, et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. JACC 1999;34:1153-62
   Google Scholar
• Fleming RM. Defining and treating heart failure. In: Chang JB editor, Textbook of angiology. Springer-Verlag, New York, NY; 1999. p. 1407-18
   Google Scholar
• Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-33
   PubMed Web of Science ®Google Scholar
• Fleming RM, Rater D, Ketcham K. Reducing cholesterol and triglycerides in the elderly patient by diet alone. The council on arteriosclerosis for the 66th Scientific Sessions of the AHA; 1993;127
   Google Scholar
• Fleming RM, Rater D. Dietary changes without medications can equally reduce cholesterol in both the young and older patient. The council on arteriosclerosis for the 66th Scientific Sessions of the AHA; 1993;128
   Google Scholar
• Fleming RM, Rater D, Ketcham K. Studying the effect of medications on cholesterol and triglycerides in subjects not receiving dietary counseling. The council on arteriosclerosis for the 66th Scientific Sessions of the AHA; 1993;128
   Google Scholar
• Fleming RM, Ketcham K. Dietary reinforcement is an integral component of cholesterol reduction. The council on arteriosclerosis for the 66th Scientific Sessions of the AHA; 1993;128
   Google Scholar
• Fleming RM, Fleming DM, Gaede R. Hyperlipidemic elderly patients: comparing diet and drug therapy. The council on arteriosclerosis for the 67th Scientific Sessions of the AHA; 1994;101
   Google Scholar
• Fleming RM, Fleming DM, Gaede R. Treatment of hyperlipidemic patients: diet versus drug therapy. The council on arteriosclerosis for the 67th Scientific Sessions of the AHA; 1994;101
   Google Scholar
• Fleming RM, Ketcham K, Fleming D, Gaede R. Controlling hypercholesterolemia by diet and drug therapy in the elderly. 1st Annual Scientific Session on Cardiovascular Disease in the Elderly; 1995
   Google Scholar
• Fleming RM. Reducing cholesterol and triglyceride levels in both the young and elderly patient by dietary changes, with and without hyperlipidemic medications. 17th World Congress of the International Union of Angiology; Westminster, London, SWI, The Royal Society of Medicine; 1995
   Google Scholar
• Fleming RM, Ketchum K, Fleming DM, Gaede R. Investigating differences in cholesterol and triglyceride levels as influenced by diet and hyperlipidemic medications. 42nd Annual World Assembly of the American College of Angiology; Maui, HI; 1995
   Google Scholar
• Fleming RM, Ketchum K, Fleming DM, Gaede R. Treating hyperlipidemia in the elderly. Angiology 1995;46:1075-83
   PubMed Web of Science ®Google Scholar
• Fleming RM, Ketchum K, Fleming DM, Gaede R. Effect of dietary counseling on hypercholesterolemia lost unless periodic counseling continues. The 69th Scientific Sessions of the AHA; 1996
   Google Scholar
• Fleming RM, Ketchum K, Fleming DM, Gaede R. Assessing the independent effect of dietary counseling and hypolipidemic medications on serum lipids. Angiology 1996;47:831-40
   PubMed Web of Science ®Google Scholar
• Fleming RM, Ketchum K, Fleming DM, Gaede R. Intensive dietary counseling a necessary adjunct to significantly increase the effectiveness of hypolipidemic medications. 5th World Congress on Heart Failure-Mechanisms and Management. Washington, DC; 1997
   Google Scholar
• Fleming RM. Assessing PET myocardial perfusion and viability in 32 patients undergoing risk factor modification. XVI World Congress of the International Society of Heart Research; Rhodes, Greece; 1998
   Google Scholar
• Fleming RM. The importance of FDG in the assessment of risk factor modification outcomes. XVI World Congress of the International Society of Heart Research; Rhodes, Greece; 1998
   Google Scholar
• Fleming RM. Determining the outcomes of risk factor modification using positron emission tomography (PET) imaging. International College of Angiology. 40th Annual World Congress; Lisbon, Portugal; 1998
   Google Scholar
• Fleming RM, Boyd L, Forster M. Unified Theory approach reduces heart disease and recovers viable myocardium. 42nd Annual World Congress International College of Angiology; San Diego, CA; 2000
   Google Scholar
• Lipsenthal L, Ornish D, Fleming RM. Diets to reduce weight and CV risk: hype or hope? Lower fat is better. 73rd AHA Scientific Sessions; 2000
   Google Scholar
• Fleming RM. The effect of low-fat, moderate fat and high fat diets on weight loss and cardiovascular disease risk factors. The Asian-Pacific Scientific Forum. 42nd Annual Conference on Cardiovascular Disease Epidemiology and Prevention; Honolulu; HI; 2002
   Google Scholar
• Fleming RM. The effect of dieting on weight loss and cardiovascular disease. 49th Annually Congress of the American College of Angiology; Maui, HI; 2002
   Google Scholar
• Fleming RM. The clinical importance of risk factor modification: looking at both myocardial viability (MV) and myocardial perfusion imaging (MPI). Intern J Angiol 2000;9:55-69
   Google Scholar
• Fleming RM, Boyd L, Forster M. Reversing heart disease in the new millennium-the Fleming Unified Theory. Angiology 2000;51:617-29
   PubMed Web of Science ®Google Scholar
• Fleming RM. The effect of high protein diets on coronary blood flow. Angiology 2000;51:817-26
   PubMed Web of Science ®Google Scholar
• Fleming RM. The effect of high, moderate and low fat diets on weight loss and cardiovascular disease risk factors. Prev Cardiol 2002;110-118.
   PubMedGoogle Scholar
• Fleming RM. Caloric intake, not carbohydrate or fat consumption, determines weight loss. Am J Med 2003;114:78
   PubMed Web of Science ®Google Scholar